Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders

Alvin V Terry, Patrick Michael Callahan, Caterina M. Hernandez

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

challenges associated with developing more effective treatments for neurologic and psychiatric illness such as Alzheimer's disease and schizophrenia are considerable. Both the symptoms and the pathophysiology of these conditions are complex and poorly understood and the clinical presentations across different patients can be very heterogeneous. Moreover, it has become apparent that the reductionist approach to drug discovery for these illnesses that has dominated the field for decades (i.e., the development of highly selective compounds or other treatment modalities focused on a very specific pathophysiologic target) has not been widely successful. Accordingly, a variety of new strategies have emerged including the development of "multitarget-directed ligands" (MTDLs), the development and/or identification of compounds that exhibit "multifunctional" activity (e.g., pro-cognitive plus neuroprotective, pro-cognitive plus antipsychotic activity), "repurposing" strategies for existing compounds that have other clinical indications, and novel "adjunctive" treatment strategies that might enhance the efficacy of the currently available treatments. Interestingly, a variety of ligands at nicotinic acetylcholine receptors (nAChRs) appear to have the potential to fulfill one or more of these desirable properties (i.e., multifunctional, repurposing, or adjunctive treatment potential). The purpose of this review (while not all-inclusive) is to provide an overview of a variety of nAChR ligands that demonstrate potential in these categories, particularly, "multifunctional" properties. Due to their densities in the mammalian brain and the amount of literature available, the review will focus on ligands of the high affinity α4β2 nAChR and the low affinity α7 nAChR.

Original languageEnglish (US)
Pages (from-to)388-398
Number of pages11
JournalBiochemical Pharmacology
Volume97
Issue number4
DOIs
StatePublished - Oct 15 2015

Fingerprint

Ligands
Nicotinic Receptors
Therapeutics
Antipsychotic Agents
Drug Discovery
Brain
Nervous System
Psychiatry
Schizophrenia
Alzheimer Disease

Keywords

  • 's disease
  • Alzheimer
  • Cholinergic
  • Memory
  • Mild Cognitive Impairment
  • Schizophrenia

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders. / Terry, Alvin V; Callahan, Patrick Michael; Hernandez, Caterina M.

In: Biochemical Pharmacology, Vol. 97, No. 4, 15.10.2015, p. 388-398.

Research output: Contribution to journalReview article

@article{c3552253056b4dc4a67195e494f2666c,
title = "Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders",
abstract = "challenges associated with developing more effective treatments for neurologic and psychiatric illness such as Alzheimer's disease and schizophrenia are considerable. Both the symptoms and the pathophysiology of these conditions are complex and poorly understood and the clinical presentations across different patients can be very heterogeneous. Moreover, it has become apparent that the reductionist approach to drug discovery for these illnesses that has dominated the field for decades (i.e., the development of highly selective compounds or other treatment modalities focused on a very specific pathophysiologic target) has not been widely successful. Accordingly, a variety of new strategies have emerged including the development of {"}multitarget-directed ligands{"} (MTDLs), the development and/or identification of compounds that exhibit {"}multifunctional{"} activity (e.g., pro-cognitive plus neuroprotective, pro-cognitive plus antipsychotic activity), {"}repurposing{"} strategies for existing compounds that have other clinical indications, and novel {"}adjunctive{"} treatment strategies that might enhance the efficacy of the currently available treatments. Interestingly, a variety of ligands at nicotinic acetylcholine receptors (nAChRs) appear to have the potential to fulfill one or more of these desirable properties (i.e., multifunctional, repurposing, or adjunctive treatment potential). The purpose of this review (while not all-inclusive) is to provide an overview of a variety of nAChR ligands that demonstrate potential in these categories, particularly, {"}multifunctional{"} properties. Due to their densities in the mammalian brain and the amount of literature available, the review will focus on ligands of the high affinity α4β2 nAChR and the low affinity α7 nAChR.",
keywords = "'s disease, Alzheimer, Cholinergic, Memory, Mild Cognitive Impairment, Schizophrenia",
author = "Terry, {Alvin V} and Callahan, {Patrick Michael} and Hernandez, {Caterina M.}",
year = "2015",
month = "10",
day = "15",
doi = "10.1016/j.bcp.2015.07.027",
language = "English (US)",
volume = "97",
pages = "388--398",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders

AU - Terry, Alvin V

AU - Callahan, Patrick Michael

AU - Hernandez, Caterina M.

PY - 2015/10/15

Y1 - 2015/10/15

N2 - challenges associated with developing more effective treatments for neurologic and psychiatric illness such as Alzheimer's disease and schizophrenia are considerable. Both the symptoms and the pathophysiology of these conditions are complex and poorly understood and the clinical presentations across different patients can be very heterogeneous. Moreover, it has become apparent that the reductionist approach to drug discovery for these illnesses that has dominated the field for decades (i.e., the development of highly selective compounds or other treatment modalities focused on a very specific pathophysiologic target) has not been widely successful. Accordingly, a variety of new strategies have emerged including the development of "multitarget-directed ligands" (MTDLs), the development and/or identification of compounds that exhibit "multifunctional" activity (e.g., pro-cognitive plus neuroprotective, pro-cognitive plus antipsychotic activity), "repurposing" strategies for existing compounds that have other clinical indications, and novel "adjunctive" treatment strategies that might enhance the efficacy of the currently available treatments. Interestingly, a variety of ligands at nicotinic acetylcholine receptors (nAChRs) appear to have the potential to fulfill one or more of these desirable properties (i.e., multifunctional, repurposing, or adjunctive treatment potential). The purpose of this review (while not all-inclusive) is to provide an overview of a variety of nAChR ligands that demonstrate potential in these categories, particularly, "multifunctional" properties. Due to their densities in the mammalian brain and the amount of literature available, the review will focus on ligands of the high affinity α4β2 nAChR and the low affinity α7 nAChR.

AB - challenges associated with developing more effective treatments for neurologic and psychiatric illness such as Alzheimer's disease and schizophrenia are considerable. Both the symptoms and the pathophysiology of these conditions are complex and poorly understood and the clinical presentations across different patients can be very heterogeneous. Moreover, it has become apparent that the reductionist approach to drug discovery for these illnesses that has dominated the field for decades (i.e., the development of highly selective compounds or other treatment modalities focused on a very specific pathophysiologic target) has not been widely successful. Accordingly, a variety of new strategies have emerged including the development of "multitarget-directed ligands" (MTDLs), the development and/or identification of compounds that exhibit "multifunctional" activity (e.g., pro-cognitive plus neuroprotective, pro-cognitive plus antipsychotic activity), "repurposing" strategies for existing compounds that have other clinical indications, and novel "adjunctive" treatment strategies that might enhance the efficacy of the currently available treatments. Interestingly, a variety of ligands at nicotinic acetylcholine receptors (nAChRs) appear to have the potential to fulfill one or more of these desirable properties (i.e., multifunctional, repurposing, or adjunctive treatment potential). The purpose of this review (while not all-inclusive) is to provide an overview of a variety of nAChR ligands that demonstrate potential in these categories, particularly, "multifunctional" properties. Due to their densities in the mammalian brain and the amount of literature available, the review will focus on ligands of the high affinity α4β2 nAChR and the low affinity α7 nAChR.

KW - 's disease

KW - Alzheimer

KW - Cholinergic

KW - Memory

KW - Mild Cognitive Impairment

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84943357229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943357229&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2015.07.027

DO - 10.1016/j.bcp.2015.07.027

M3 - Review article

VL - 97

SP - 388

EP - 398

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 4

ER -